According to a recent LinkedIn post from HistoSonics, the company plans to engage surgeons and oncology specialists at the Society of Surgical Oncology conference in Phoenix, AZ, from March 5–7. The post highlights an educational focus on disease-specific content and programming for advanced practice providers, residents, and fellows, indicating outreach to both current and emerging clinical decision-makers.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post also describes a peer-driven dinner forum titled “Histotripsy in Practice: A Clinical Forum,” featuring surgical oncology leaders from MD Anderson Cancer Center at Cooper and NE Georgia Medical Center, moderated by HistoSonics’ Medical Director. This format suggests an effort to deepen physician education and encourage early adoption of histotripsy among influential practitioners, which could support longer-term procedure volume growth.
In addition, the company’s LinkedIn post notes that its team will be available at booth #821 to discuss the Edison Histotripsy System, positioning the conference as a venue for hands-on engagement with potential users. For investors, this activity may indicate continued commercialization efforts, particularly in liver applications, while the disclaimer that use outside the liver is limited to clinical investigations underscores the current regulatory boundaries and the need for further clinical and regulatory progress.